Statement of Principles concerning malignant neoplasm of the cervix (Reasonable Hypothesis) (No. 80 of 2020)

The SoP organises entitlement logic around a few core legal-medical concepts: the statutory disease definition (what counts as malignant neoplasm of the cervix), the set of qualifying factors that raise a reasonable hypothesis, the necessary relation of any such factor to relevant service, and cross-application rules where other SoPs cover linked injuries or diseases.

Disease definition and coding

• The SoP defines malignant neoplasm of the cervix in statutory terms (section 7(2)). This definition takes precedence over mere diagnostic coding: while it notes that the condition "attracts ICD‑10‑AM code C53 or D06" (section 7(3)), subsection 7(3) and 7(4) make clear that the legal meaning is the description in section 7(2), and the ICD-10-AM code is referenced only as the code assigned in the Australian modification of ICD-10 (Tenth Edition, effective 1 July 2017).

Reasonable hypothesis standard

• This instrument is engaged at the "reasonable hypothesis" stage for claims under the VEA/MRCA. Section 9 prescribes the discrete factual or medical circumstances that, if found and connected to relevant service (section 10(1)), are sufficient to raise that reasonable hypothesis. The legal consequence flows from the VEA/MRCA machinery, not from the SoP alone.

Enumerated qualifying factors

• Section 9 lists nine categories (9(1)-9(9)). Key elements include: persistent infection with a specified HPV type before clinical onset (9(1)); HIV infection before clinical onset (9(2)); a smoking exposure criterion for squamous cell carcinoma only (9(3)) with a quantitative pack-year threshold and time-since-cessation rule; combined oral contraceptive pill use for specified duration and timing (9(4)); immunosuppressive drug use post-organ/tissue transplantation (9(5)); systemic lupus erythematosus in a specified pre-onset window (9(6)); prevention from accessing screening, with further conditions, within seven years before clinical onset (9(7)); prevention from accessing appropriate treatment for precancerous lesions in the 2-7 year window prior to onset (9(8)); and inability to obtain appropriate clinical management for malignant neoplasm (9(9).) Each factor has precise temporal and definitional limits in the SoP.

Temporal and service-relationship constraints

• Section 10(1) imposes a service-relationship requirement: a factor must be related to relevant service. Section 10(2) narrows the application of subsection 9(9), making it applicable only to material contribution to, or aggravation of, the disease where the person’s malignant neoplasm of the cervix was suffered or contracted before or during (but did not arise out of) the person's relevant service.

Cross-linking with other SoPs

• Section 11 enforces the primacy of other SoPs where a factor in section 9 refers to a disease or injury that is itself the subject of another SoP. In that situation, the factors in the other SoP apply "in accordance with the terms of that Statement of Principles as in force from time to time." This creates dependency chains: for example, where HIV infection or organ transplantation raises issues governed by separate SoPs, the content of those SoPs is operative for evaluation.

Definitions and thresholds

• Schedule 1 provides critical definitional thresholds and lists. Examples highly material to the outcome include:
  • specified human papillomavirus types (a list of types 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 67, 68, 70, 73, 82);
  • persistent infection is defined as infection by the same HPV type for at least two consecutive years;
  • one pack-year is quantified and includes conversion rules and worked examples (Schedule 1, one pack-year note);
  • clinical screening is defined to include HPV testing or Pap cytology examinations.

RMA’s evidentiary stance

• Section 8 records the RMA’s view that "sound medical‑scientific evidence" indicates malignant neoplasm of the cervix can be related to relevant service. That recorded view underpins the SoP’s content and frames the list of qualifying factors as the RMA’s determination of the medical/scientific evidence sufficient to raise the reasonable hypothesis.

Instrumental role in claims processing

• The SoP is an administrative/medical benchmark designed to be applied by decision-makers in the VEA/MRCA claim processes. It does not re-write statutory eligibility criteria but instead supplies the medical nexus assessment that feeds into statutory decision-making.

Primary affected groups

• Veterans and former members of the Australian Defence Force who lodge claims under section 120A of the VEA or section 338 of the MRCA. The SoP explicitly applies to claims to which those provisions apply (section 5).
• Members of Peacekeeping Forces and other categories covered by the definition of relevant service in the Schedule, because relevant service is the gateway for connecting a listed factor to service (Schedule 1, relevant service).

Decision-makers and government agencies

• Department of Veterans' Affairs (DVA) decision-makers and adjudicators who administer claims under the VEA and MRCA will use this SoP as an evidentiary benchmark for medical nexus. The instrument is made by the RMA under statutory authority, and its factors are the RMA’s determination of the medical-scientific evidence to apply in that administrative context (section 3 and section 8).

Medical practitioners and record custodians

• Treating clinicians, pathologists, cytologists, hospital records officers and private practitioners will be indirectly affected insofar as claimants, decision-makers and advisers will require medical records and clinical testing results that align with the SoP’s definitions and timing requirements (for example, HPV genotyping records showing persistence of the same type for two consecutive years, or documentation of immunosuppressive drug therapy and transplant dates).

Legal and claims advisors

• Lawyers, advocates and consultants who prepare and prosecute VEA/MRCA claims will need to marshal evidence that fits the specific factors and timing windows. The SoP narrows the scope of what will raise a reasonable hypothesis and thus shapes evidentiary strategy.

Who does not gain automatic new rights

• The SoP itself does not establish a new entitlement outside the VEA/MRCA statutory processes. It does not create private causes of action, civil liabilities, criminal offences, or standalone compensation rights. Its effect is administrative: it sets the circumstances that raise a reasonable hypothesis for the purposes of statutorily authorised claims processes (section 5).

Distribution of benefits and burdens

• Beneficiaries will be claimants who can document at least one of the listed factors and show that it was related to their relevant service. The act of documenting certain factors may be easier for those who have continuous medical records (pathology, smears, prescriptions), and harder for those without such records. The SoP’s timing and specificity therefore concentrate practical benefit on claimants with preserved records showing the requisite factors and times; conversely, it imposes evidentiary burdens on claimants lacking contemporaneous documentation.

Service categories and scope

• Schedule 1 defines relevant service across both VEA and MRCA categories: operational, peacekeeping, hazardous, British nuclear test defence service (VEA), and warlike and non-warlike service (MRCA). Any claim by a person outside those service categories would fall outside the SoP’s application (Schedule 1, relevant service).

Amendment impacts on affected parties

• The instrument has been amended (see Endnote 3: registration and commencement dates; Endnote 4 indicates specific amendments to the one pack-year definition and to a note to s9(3)). Affected parties should check the version in force on the relevant date because amendments may alter threshold calculations (e.g., pack-year conversions) that matter for claims.

This SoP is not a statute that imposes criminal duties; rather, it prescribes medical/administrative benchmarks for use in statutory claims under the VEA and MRCA. Duties and rights therefore arise through the interaction of the SoP with the underlying statutes and administrative processes.

Rights created or clarified for claim assessment

• Right to an assessment by reference to the RMA-determined factors: where a claimant establishes (on the evidence) at least one of the factors in section 9 and shows it is related to their relevant service (section 10(1)), a "reasonable hypothesis" will be raised that their malignant neoplasm of the cervix (or death from it) is connected to service. That reasonable hypothesis is a legal evidential threshold within the VEA/MRCA claims process. The SoP thus gives claimants a structured list of factual bases on which to rest a medical nexus claim.

Decision-maker duties (administrative application)

• Decision-makers who apply the VEA/MRCA must take into account the SoP as the RMA’s statutory determination of the medical evidence sufficient to raise a reasonable hypothesis. While the SoP does not itself say "decision-maker must do X", the statutory architecture gives the RMA authority to make Statements of Principles for use in claims (see section 3 and subsection 196B(2) of the VEA, cited as the source of power in section 3). Practically, decision-makers are bound to apply the SoP in adjudicating nexus where appropriate, because these Statements are integral to the statutory claims framework.

Claimant evidentiary obligations

• Claimants must produce or allow retrieval of medical or service records that demonstrate a qualifying factor and the connection to relevant service. The SoP’s factors contain specific timing and content thresholds that turn on documentary proof: for example, documented persistent infection with the same HPV type for at least two consecutive years (Schedule 1, persistent infection); records of combined oral contraceptive pill use for at least three continuous years with a specified start and cessation timeline (section 9(4)); smoking history measured in pack-years with the numeric conversion rules (section 9(3) and Schedule 1 notes). The duty to adduce such evidence is practical and evidentiary rather than a statutory duty imposed by the SoP itself.

Cross-application duty where other SoPs apply

• Section 11 creates an administrative duty to follow other relevant SoPs if a factor in section 9 refers to another injury or disease that is itself the subject of a separate SoP. In those cases, "the factors in that Statement of Principles apply in accordance with the terms of that Statement of Principles as in force from time to time." This requires adjudicators and advisers to map dependencies between SoPs and apply the up-to-date terms of the other instrument.

No criminal penalties or private civil rights created

• The instrument contains no penalties, fines, or civil private rights of action. It functions as an administrative medical benchmark. Therefore, unlike primary legislation that creates offences or civil liabilities, this instrument’s content operates only within the statutory claims framework.

Limits on applicability and rights to rely

• The SoP requires that any factor relied on be related to relevant service (section 10(1)). If the factor is not related to service, a claimant cannot rely on it to raise the reasonable hypothesis for the purposes of a VEA/MRCA claim. Additionally, subsection 10(2) clarifies that the inability to obtain appropriate clinical management (9(9)) is only applicable to material contribution or aggravation where the disease was suffered or contracted before or during (but did not arise out of) relevant service. Practitioners should note that these limits affect whether a claimant has a right to have a reasonable hypothesis found.

Administrative review and amendment risk

• Because section 11 requires cross-application with other Statements as "in force from time to time", rights and duties can change when those other instruments are amended. The SoP itself has been amended (see endnotes), and further amendments to any linked SoP can change the evidentiary configuration for claimants and decision-makers.

This Statement of Principles is an administrative medical instrument; it contains no criminal offences, pecuniary penalties, or direct enforcement provisions. It is not an enforcement instrument in the criminal or regulatory sense. The SoP’s legal effect is functional and evidentiary within the VEA/MRCA claims regime rather than punitive.

How the SoP is enforced administratively

• The SoP operates as a prescribed evidentiary standard used by decision-makers in the DVA and by adjudicators in the claims processes established in the VEA and MRCA. Sections 5 and 8 make the SoP’s application and evidentiary underpinning explicit: it applies to claims under section 120A of the VEA and section 338 of the MRCA (section 5), and section 8 records the RMA’s view that there is sound medical‑scientific evidence supporting the linkage between the disease and relevant service. The "enforcement" mechanism is therefore administrative: decision-makers must apply the SoP when assessing whether a reasonable hypothesis has been raised.

No penalties inside the instrument

• The instrument contains no provision imposing monetary penalties, fines, criminal sanctions, or disciplinary measures on persons who do or do not take specified actions. It does not, for example, make non-disclosure an offence. Any sanctioning or adverse findings must arise under other statutory provisions of the VEA, MRCA or other legislation, not from this SoP itself.

Appeal, review and redress pathways

• The SoP does not set out review, appeal or merits-review procedures; those processes (including rights of review, merits review, and judicial review) are contained in the VEA and MRCA and their associated administrative and tribunal frameworks. The SoP will be a piece of evidence or a statutory benchmark used within those review processes but does not itself prescribe appeal rights or procedures.

Practical enforcement implications for decision-makers

• Decision-makers who ignore the SoP when it is directly applicable to a claim may expose their decisions to legal challenge in the usual administrative-law pathways, because the RMA is the statutory body authorised to determine SoPs for use in claims under the VEA/MRCA. The instrument thereby carries de facto enforcement force in the sense that it is a controlling evidential standard in the statutory decision framework. However, the SoP provides no independent enforcement mechanism to police compliance with its application.

Operational compliance and record checks

• The practical "enforcement" of the SoP’s standards will come through administrative processes: requests for medical records, requests for pathology and cytology results, subpoenas or authorisations for private medical records where statutory powers permit, and routine medical assessments or independent medical examinations procured by DVA. These are functions of the broader claims process rather than of the SoP directly.

Amendment and currency as an enforcement issue

• Section 11’s instruction to apply other relevant SoPs "as in force from time to time" means that the currency of the SoP and linked instruments matters for claims. Administrative enforcement therefore includes ensuring the version in force at the relevant time is applied. The endnotes record amendments and commencement dates (Endnotes 3 and 4), which are operationally significant for decision-makers and claimants.

The SoP is expressly designed to interface with the statutory claims frameworks in the VEA and MRCA and to reference other Statements of Principles where relevant. It interacts with other laws and instruments in several ways.

Authority and statutory embedding

• The SoP is made under subsection 196B(2) of the VEA (section 3). That statutory source authorises the RMA to determine Statements of Principles for use in the VEA/MRCA claims systems. The SoP itself applies to claims where the statutory provisions of the VEA and MRCA apply (section 5). Therefore the SoP is an administrative element within the VEA/MRCA legal framework, not freestanding legislation. Any legal effect derives from that statutory embedding.

Interaction with other SoPs

• Section 11 provides for direct interaction with other Statements of Principles. If a factor in section 9 refers to an injury or disease that is the subject of another SoP, that other SoP’s factors apply. This creates a web of cross-references between instruments. Practically, adjudicators must identify whether a factor in section 9 invokes another SoP and then determine the facts in accordance with the current terms of that other instrument. This linkage means that changes to other SoPs will alter how certain factors in this SoP are assessed.

Interface with clinical coding systems and medical records law

• The SoP references ICD‑10‑AM codes (section 7(3)-(4)) but emphasises that its legal meaning is the statutory description in section 7(2). Hence, while ICD‑10‑AM codes can assist in classifying the clinical entity, they do not alter the statutory definition. Adjudicators will therefore consider both the legal description and any coding used in health records. Interaction with privacy and medical-records laws is indirect: decision-makers require access to medical records to apply the SoP, and that process must follow the privacy, consent and disclosure rules in other applicable laws (privacy and health records legislation), though those processes are outside the SoP itself.

Relation to VEA and MRCA substantive and procedural rules

• The instrument applies to claims to which particular VEA and MRCA provisions apply (section 5). The SoP therefore intersects with the VEA/MRCA on issues such as: causation standards, statutory time limits, entitlement thresholds, decision-making processes, and appeal/review mechanisms. The SoP supplies a medical nexus test feeding into those statutory processes.

Amendment and legislative hierarchy

• The endnotes show the SoP’s amendment history (Endnotes 3 and 4). The SoP is subordinate to primary legislation: the RMA’s determinations must be made under statutory authority and can be amended or superseded under the enabling statute. Practitioners must therefore consult the current version and consider how amendments (for example, the 2022 amendment to "one pack-year") interact with existing VEA/MRCA claims.

No conversion into civil/common law causes

• The SoP does not create private civil-law rights outside the VEA/MRCA framework. It is not stated to be evidence in other contexts (for example, in private tort litigation) and the instrument says nothing about admissibility in other courts or tribunals. Any use of the SoP outside its statutory claims context would be purely persuasive and governed by the rules of evidence and relevance in the forum concerned; those interactions are not addressed in the instrument.

Cross-jurisdictional medical standards

• The SoP uses the phrase "contemporary medical standards of the time" in sections 9(7) and 9(8) when describing access to screening and treatment, which requires adjudicators to assess standards against the clinical practice relevant to the period in question. That assessment will implicate clinical guidelines, expert evidence, and possibly other regulatory instruments governing medical practice, but those instruments are not named here. The SoP thus creates an evidentiary need to engage with broader medical standards and their temporal application.

The SoP has a concise legislative history recorded in the endnotes appended to the compilation. The endnotes are part of the instrument’s published compilation and must be consulted for amendment and commencement details.

Key dates and amending instruments

• Original registration and commencement: Statement of Principles concerning malignant neoplasm of the cervix (Reasonable Hypothesis) (No. 80 of 2020) was registered on 2 November 2020 (F2020L01381) and commenced on 30 November 2020 (Endnote 3).
• Amendment: Veterans' Entitlements (Statements of Principles,definition of "one pack-year") Amendment Determination 2022 (No. 94 of 2022) was registered 26 August 2022 (F2022L01128) and commenced on 19 September 2022. The compilation notes that this Amendment Determination’s day of commencement is 19 September 2022 (front matter of compilation and Endnote 3).

Nature of the 2022 amendment

• Endnote 4 identifies that the Schedule 1 - Dictionary definition of "one pack-year" was amended by the No. 94 of 2022 instrument (Endnote 4 entries). The main text of Schedule 1 now includes conversion notes (Note 1 and Note 2) specifying that one pack-year equals smoking 20 cigarettes per day for one year or an equivalent weight of 7,300 grams of smoking tobacco, and providing examples of calculation. The amendment also adjusted a note to subsection 9(3). The 2022 amendment therefore changes the quantitative and conversion method for assessing smoking exposure, which is consequential for claims relying on the smoking factor in section 9(3).

Compilation commentary and uncommenced amendments

• The compilation states that it shows the text "as amended and in force on 19 September 2022" and notes that uncommenced amendments (if any) are not reflected in the text (front matter). Practitioners should consult the legislation register for any amendments made after the compilation date or any amending laws not yet commenced (front matter).

How amendments affect application

• Because section 9(3) uses "at least 10 pack-years of tobacco products" and Schedule 1 defines "one pack-year" and sets out the calculation (with numerical conversion and examples), amendments to the pack-year definition change the evidentiary threshold for meeting factor 9(3). This is an example of how a technical change in a Schedule definition has practical effect on the operation of a substantive factor.

Endnote record-keeping

• Endnote 3 provides the chronological list of the instrument and its amendment(s), including registration and commencement dates. Endnote 4 sets out at provision level how specific sections were affected. The compilation emphasises that if the operation of a provision or amendment is affected by an application, saving or transitional provision not included in the compilation, details are included in the endnotes.

Practical implication of amendment history

• Practitioners and decision-makers must determine which version of the SoP was in force at the relevant time for the claim. Because the SoP is used in assessing claims, the amendment dates and commencements can materially affect whether a claimant meets the numerical or temporal thresholds at the relevant date. The instrument’s endnotes identify the authoritative commencement dates and amendment particulars.

The SoP text and its endnotes do not record any judicial decisions interpreting, applying, or otherwise litigating this particular Statement of Principles. The instrument’s published compilation contains no citations to case law or litigation outcomes, nor does it name any cases.

What the instrument records instead

• The endnotes record only the legislative history and amendment history (Endnotes 3 and 4). They do not purport to summarise or list tribunal or court decisions. The SoP itself is a statutory administrative instrument and its legal role is to guide administrative decision-makers in relation to claims under the VEA and MRCA.

Implication for practitioners

• Because the SoP publication provides no litigation history, practitioners should not assume settled judicial interpretations exist from this instrument alone. Where legal argument depends on the interpretation of a SoP’s terms (for example, how to apply the smoking cessation time-limits in section 9(3), or what constitutes "being prevented from accessing clinical screening" in section 9(7)), reliance must be on the statutory text, medical evidence, and any relevant primary legislation or tribunal/court decisions found by independent legal research. The instrument itself does not cite or summarise any decisions.

Recommendation for claim strategists

• If contesting a decision where the SoP is central, gather authoritative clinical evidence and, if available, identify any tribunal decisions under the VEA/MRCA addressing similar SoPs or similar factual issues. The SoP’s absence of litigation references means decision-makers and advocates must depend upon the statutory language, expert medical evidence and any case law in the broader VEA/MRCA context identified through independent legal research.

The SoP includes numerous technical and timing requirements that can materially determine whether a claimant raises the reasonable hypothesis. These are the practical "gotchas" that commonly trip up claimants and advisers:

1. Disease definition vs ICD coding

• The SoP’s legal definition of malignant neoplasm of the cervix is the descriptive text in section 7(2), not the ICD code alone (section 7(3)-(4)). Even if a medical record uses an ICD‑10‑AM code C53 or D06, the legal test requires that the disease meet the statutory description (section 7(2)). Conversely, conditions expressly excluded by section 7(2)(c) (for example, CIN grades 1-2, melanoma, neuroendocrine tumours, soft tissue sarcoma and certain lymphomas) do not fall within the SoP even if their codes might superficially appear similar.

2. Smoking factor applies only to squamous cell carcinoma

• Section 9(3) is limited to "for squamous cell carcinoma of the cervix only." If a claimant’s pathology shows adenocarcinoma or adenosquamous carcinoma, the smoking pack-year factor cannot be used to raise the reasonable hypothesis.

3. Pack-year calculation and conversion specificity

• The SoP’s Schedule 1 definition of "one pack-year" was amended (No. 94 of 2022). It now equates one pack-year with 20 cigarettes per day for one year or an equivalent amount of tobacco (7,300 grams of smoking tobacco by weight). The Schedule also supplies conversion rules and worked examples (e.g., smoking 10 cigarettes per day for 10 years equals 5 pack-years) (Schedule 1 , one pack-year notes). Failure to apply the current conversion or to produce precise smoking-history evidence can lead to rejection of the smoking factor.

4. Temporal windows are precise and frequently absolute

• Many factors are tied to precise timing windows. Examples:
  • Smoking: at least 10 pack-years and at least two years before clinical onset; if smoking ceased, clinical onset must be within 20 years of cessation (section 9(3)).
  • Combined oral contraceptive pill: continuous use for at least three years, commencing at least five years before clinical onset; if ceased, clinical onset must be within 15 years of cessation (section 9(4)).
  • Immunosuppressive drugs post-transplantation: at least two years before clinical onset (section 9(5)).
  • Systemic lupus erythematosus (SLE): within five years before clinical onset (section 9(6)).
  • Prevention from accessing screening: within seven years before clinical onset, and if screening later resumed, there must have been no normal test result and the opportunity for subsequent screening must not have been declined (section 9(7)(a)-(b)).
  • Prevention from accessing appropriate treatment for precancerous lesions: between two and seven years before clinical onset (section 9(8)).
• These strict windows mean that imprecise record dates or gaps in records can defeat an otherwise plausible causal narrative.

5. Persistent infection requires same HPV type for at least two consecutive years

• Section 9(1) relies on "persistent infection of the cervical epithelium with a specified human papillomavirus before the clinical onset." Schedule 1 defines persistent infection as infection by the same HPV type for at least two consecutive years. Mere evidence of HPV presence without genotype continuity over two consecutive years is insufficient under this criterion.

6. Specified HPV types are enumerated

• Only the listed HPV types in Schedule 1 (e.g., 16, 18, 31, 33, 45 etc.) are "specified human papillomavirus." A positive HPV result for a type not in the list does not meet the "specified" criterion.

7. Prevention from accessing screening/treatment requires proof of prevention and follow-up conduct

• For factor 9(7) (prevented from accessing clinical screening), the SoP requires evidence not only of prevention but, if screening resumed, that there was "no normal test result" and that the opportunity to be screened subsequently "has not been declined." This requires proof of both the prevention event and the claimant’s subsequent testing behaviour/results, which increases evidentiary complexity.

8. Relation to relevant service is mandatory

• Section 10(1) requires that any factor relied upon be "related to the relevant service rendered by the person." Good clinical evidence alone is not enough; the causative factor must be connected to service through the usual statutory nexus requirements.

9. Limitation on factor 9(9)

• The inability to obtain appropriate clinical management (9(9)) is narrower in application if the disease was suffered or contracted before or during service: it then applies only to material contribution to, or aggravation of, the disease (section 10(2)). This nuance affects claims where disease onset predates service.

10. Cross-reference with other SoPs can change assessment

• Where a factor refers to a disease covered by another SoP (section 11), the terms of that other SoP apply "as in force from time to time." That means a seemingly straightforward factor (for example, HIV infection) may trigger a different set of criteria and timing requirements under the HIV SoP; failing to consult the other SoP can miss material differences.

11. "Clinical onset" is the anchor date

• Many timing rules use "clinical onset" of malignant neoplasm. Determining the clinical onset date can be contentious and will usually require expert medical evidence; administrative decisions may rely on pathology reports, imaging or clinician notes to fix that date.

12. Death from malignant neoplasm includes terminal events

• Section 7(5) defines death from malignant neoplasm to include death from a terminal event or condition that was contributed to by the cancer. Schedule 1 defines terminal event broadly (pneumonia, respiratory failure, cardiac arrest, circulatory failure, cessation of brain function). Practitioners should ensure death certificates and clinical cause-of-death material show that malignant neoplasm of the cervix contributed to the terminal event if death-based claims are advanced.

13. Version control risks

• Because the SoP (and linked SoPs) can be amended, advisers must ensure they use the version in force at the relevant time. The endnotes show recorded amendments and commencement dates (Endnotes 3 and 4).

For claimants, legal advisers and medical practitioners preparing or assessing claims under the VEA/MRCA that rely on this SoP, compliance requires careful evidence-gathering to meet the precise factual and timing requirements in section 9 and the Schedule. Below is a pragmatic checklist and process-oriented steps rooted in the SoP’s wording.

1. Establish the disease and clinical onset date

• Obtain pathology reports, operative notes, cytology and histology reports that identify malignant neoplasm of the cervix as defined in section 7(2). Ensure the pathology sub-type (e.g., squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma) is recorded because some factors (e.g., smoking) apply only to squamous cell carcinoma (section 9(3)).
• Determine the clinical onset date with medical evidence: this date anchors temporal windows in the SoP (sections 9(1)-(9), Schedule 1).

2. For HPV-based factors (section 9(1))

• Obtain HPV test results with genotype information showing the same specified HPV type across two consecutive years (Schedule 1 definition of persistent infection).
• Confirm that the HPV types detected are among the listed "specified human papillomavirus" types in Schedule 1.
• If genotype testing is missing, consider whether reasonably contemporaneous clinical records and expert evidence can establish persistent infection, but be aware the SoP requires same-type persistence for at least two consecutive years.

3. For HIV factor (section 9(2))

• Obtain documented diagnosis dates, laboratory test results and clinical notes that show infection with human immunodeficiency virus before the clinical onset of malignant neoplasm.

4. For smoking factor (section 9(3))

• Collect detailed smoking history documentation: medical records, smoking cessation records, occupational health files, personal statements corroborated by contemporaneous evidence.
• Apply the Schedule 1 pack‑year definition and conversion rules (one pack-year = 20 cigarettes/day for one year or 7,300 g of smoking tobacco) and calculate pack‑years precisely. Remember the factor requires at least 10 pack-years of tobacco products, and if cessation occurred, clinical onset must be within 20 years of cessation.
• Verify that the cancer subtype is squamous cell carcinoma; otherwise this factor is inapplicable.

5. For combined oral contraceptive pill factor (section 9(4))

• Obtain prescription records or pharmacy dispensation records showing continuous use of combined oral contraceptive pills for at least three years, commencing at least five years before clinical onset. If use ceased, establish that clinical onset occurred within 15 years of cessation.

6. For immunosuppressive drug / transplant factor (section 9(5))

• Get transplant surgery dates, immunosuppressive medication records, hospital discharge summaries showing immunosuppressive therapy was taken at least two years before clinical onset.

7. For autoimmune disease factor (section 9(6))

• Provide medical records confirming diagnosis of systemic lupus erythematosus and that the diagnosis or manifestations were present within five years before clinical onset.

8. For prevention from accessing screening (section 9(7))

• Collate service records, clinic appointment records, communications demonstrating that the person was prevented from accessing screening in accordance with contemporary medical standards within the seven years before clinical onset.
• If screening later resumed, include all subsequent screening test results and show there has been no normal test result. Also build evidence showing that the claimant did not decline opportunities for subsequent screening (section 9(7)(a)-(b)).

9. For prevention from accessing treatment for precancerous lesions (section 9(8))

• Secure medical records showing diagnosis of cervical precancerous lesions and records showing that appropriate treatment was prevented between two and seven years before clinical onset. Define "appropriate treatment" against contemporary medical standards, using clinical guidelines and expert reports if necessary.

10. For inability to obtain appropriate clinical management of malignant neoplasm (section 9(9))

• If the disease was present before or during (but did not arise out of) relevant service, document how inability to obtain appropriate clinical management materially contributed to or aggravated the disease (see section 10(2)). Evidence could include hospital denial records, referral delays, or documented refusal or incapacity of health services connected to service circumstances.

11. Prove relation to relevant service (section 10(1))

• For every factor relied upon, provide evidence linking that factor to the claimant’s relevant service as defined in Schedule 1. This may require service records, operational reports, unit medical records, or other contemporaneous documentation indicating when and how service conditions caused, exacerbated, or prevented treatment/screening for the factor invoked.

12. Check for cross-SoP dependencies (section 11)

• Identify if any factor invokes another SoP (for example, organ transplantation or HIV may have separate SoPs). Obtain and apply the current terms of any linked SoP "as in force from time to time" to ensure compliance with their factors and thresholds.

13. Prepare expert evidence where necessary

• For contentious questions (e.g., whether screening practices during service met "contemporary medical standards of the time", whether an observed HPV pattern proves persistent infection, the correct clinical onset date), obtain contemporaneous clinician reports or independent expert reports to bridge gaps in records and interpret technical medical issues.

14. Maintain version-control and date-specific application

• Determine which version of the SoP was in force at the time relevant to the claim. Use the commencement and amendment dates recorded in the endnotes (Endnote 3 and 4) to ensure calculations (notably the pack-year rule since its 2022 amendment) are applied correctly.

15. Collate documents to support the administrative pathway

• Compile a dossier including: pathology and histology reports, cytology (Pap) and HPV test results with genotyping, prescribing and dispensing records, hospital discharge summaries, transplant operation notes, immunosuppressive drug prescriptions, smoking history records, service medical records, correspondence showing prevention from screening/treatment, and any post-service follow-up tests/results.

16. Expect administrative evidence requests

• DVA or MRCA decision-makers may request additional records, independent medical examinations, or clarification. Respond promptly and, where necessary, obtain written consents to retrieve private medical files.

17. Address gaps proactively

• If records are missing, prepare witness statements explaining reasonable attempts to obtain records, use supporting documentary evidence where contemporaneous records do not exist, and obtain expert medical opinions tying the available evidence to the SoP criteria.

18. Record and explain deviations

• If a factor is partially satisfied (for example, smoking history near the 10 pack-years threshold), quantify the shortfall precisely and present medico-legal argument about why the threshold should be read in context, supported by expert opinion. Remember that the SoP sets the RMA’s medical benchmarks; persuasive arguments against the SoP’s thresholds in a particular claim must engage medical evidence and legal pathways in the VEA/MRCA framework.

19. Seek cross-disciplinary support

• Because the SoP requires medical specificity and legal connection to relevant service, coordinated work between medical experts, service records specialists, and legal advisers is recommended.

20. Monitor amendments and linked SoPs

• Maintain awareness of amendments to this SoP and to any SoPs it references. The instrument’s endnotes record past amendments; subscribe to the legislation register or RMA publications for future changes.

Use this procedural approach to ensure documentary sufficiency for the particular factor(s) invoked. The SoP sets precise, often quantitative tests; compliance requires matching evidence to those tests rather than abstract clinical narratives alone.